SOURCE-LINKED STUDY SUMMARY
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
Full paper summarizedQuality not appraised
- What was studied
- This full-text EASL-EASD-EASO guideline updated definitions, screening, diagnosis, prevention, and treatment recommendations for metabolic dysfunction-associated steatotic liver disease.
- Who / model studied
- The guidance concerns adults with or at risk for MASLD, especially people with type 2 diabetes, abdominal obesity plus another metabolic risk factor, or abnormal liver tests.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- It recommends stepwise fibrosis assessment with FIB-4 followed by elastography when indicated. GLP-1 drugs may be used for diabetes or obesity, but were not recommended as MASH-targeted therapy without phase 3 histology evidence.
- Limitations & context
- Recommendations combined graded evidence with expert consensus; some guidance was created despite limited supporting literature.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s00125-024-06196-3